key: cord-0714099-v1o2jbkn
authors: Hauser, Blake M.; Sangesland, Maya; St. Denis, Kerri J.; Lam, Evan C.; Case, James Brett; Windsor, Ian W.; Feldman, Jared; Caradonna, Timothy M.; Kannegieter, Ty; Diamond, Michael S.; Balazs, Alejandro B.; Lingwood, Daniel; Schmidt, Aaron G.
title: Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting
date: 2022-03-07
journal: Cell Rep
DOI: 10.1016/j.celrep.2022.110561
sha: f34aeeb751c6d18cf7e6c8df6b3011d08074c385
doc_id: 714099
cord_uid: v1o2jbkn

Eliciting antibodies to surface-exposed viral glycoproteins can generate protective responses that control and prevent future infections. Targeting conserved sites may reduce the likelihood of viral escape and limit spread of related viruses with pandemic potential. Here, we leverage rational immunogen design to focus humoral responses on conserved epitopes. Using glycan engineering and epitope scaffolding in boosting immunogens, we focus murine serum antibody responses to conserved receptor binding motif (RBM) and domain (RBD) epitopes following SARS-CoV-2 spike imprinting. Whereas all engineered immunogens elicit a robust SARS-CoV-2-neutralizing serum response, the RBM-focusing immunogens exhibit increased potency against related sarbecoviruses, SARS-CoV, WIV1-CoV, RaTG13-CoV, and SHC014-CoV; structural characterization of representative antibodies defines a conserved epitope. Furthermore, the RBM-focused sera confer protection against SARS-CoV-2 challenge. Thus, RBM focusing is a promising strategy to elicit breadth across emerging sarbecoviruses without compromising SARS-CoV-2 protection. Broadly, these engineering strategies are adaptable to other viral glycoproteins for targeting conserved epitopes.

The emergence of SARS-CoV-2 (SARS-2) and the subsequent global pandemic have highlighted 56 the disruptive threat posed by viruses for which humans have no prior immunity. Rapid vaccine 57 development has led to an unprecedented number of candidates. While differing in platform (e.g., 58 mRNA, adenovirus, nanoparticle), the primary immunogen is the SARS-2 spike ectodomain 59 (Amanat and Krammer, 2020). With the continued global spread of SARS-2, in conjunction with 60 potential vaccinations, it is likely that a large proportion of the global population will eventually 61 develop an immune response to SARS-2. However, even after potentially achieving herd immunity 62 sufficient to slow its spread, further SARS-2 evolution leading to variants that escape immunity as 63 well as emerging novel coronaviruses with pandemic potential remain a concern. Elicited 64 immunity to SARS-2 infection may not protect against emergent novel coronaviruses that are to steric interference by the RBM hg engineered glycans. The Cocktail hg cohort had a modest 240 increase in RBM focusing relative to the Trimer hg cohort. This may be due to increasing the overall 241 antigenic distance (i.e., sequence difference) between the WIV1 and SARS-1 RBDs relative to 242 SARS-2 while maintaining the identical SARS-2 RBM epitope. Additionally, we find that the 243 Trimer hg and Cocktail hg cohorts had significantly lower titers to SARS-1 and WIV1 RBDs than to 244 SARS-2 RBD (Fig. S3B, C) . This difference was most pronounced in the Cocktail hg cohort, 245

suggesting that the hyperglycosylation and engineered mutations within the RBD dampened 246 responses to conserved, cross-reactive epitopes present outside the RBM. Furthermore, serum 247 titers against the rsSARS-1 and rsWIV1 RBDs were comparable to SARS-2 RBD, indicating that 248 there is minimal antibody response directed towards wild-type SARS-1 and WIV1 RBD epitopes 249 in comparison to the SARS-2 RBM (Fig. 2B) . We observed no significant glycan-dependent serum 250 response in either the Trimer hg or Cocktail hg cohort (Fig. S3G) . Collectively, these data confirm 251 an enhanced SARS-2 RBM-focused serum response elicited by our engineered immunogens. 252

To determine whether the RBM hg and Trivalent cohorts successfully directed the immune response 254 to non-RBM epitopes on the RBD, we performed serum competition by incubating RBD-coated 255 ELISA plates with B38, P2B-2F6, CR3022, and S309 IgGs, representing each of the four 256 previously defined "classes" of SARS-CoV-2 RBD epitopes ( Fig. 2C ) (Barnes et al., 2020b) . 257

Indeed, the previously characterized CR3022 and S309 antibodies have footprints that together 258 cover much of the conserved non-RBM region of the RBD, with epitope buried surface area (BSA) 259 of 917 Å 2 and 795 Å 2 respectively in comparison to BSA of 869 Å 2 for ACE2 (Lan et al., 2020; 260 Pinto et al., 2020; Yuan et al., 2020) . We then assessed binding of mouse serum IgG (Fig. 2D) . 261

Only the Trivalent cohort showed a significant increase in serum competition when CR3022 and 262 S309 IgGs are combined, suggesting that only this regimen could effectively focus to conserved 263 non-RBM epitopes on the SARS-2 RBD. 264 265

Sarbecoviruses 267

We next compared the neutralization potency (i. e., neutralization per unit of antigen-specific IgG) 268 of all cohorts using SARS-1, SARS-2, WIV1, RaTG13-CoV (RaTG13), and SHC014-CoV 269 Trimer hg and Cocktail hg cohorts also neutralized SARS-1, WIV1, RaTG13, and SHC014 276 expressing pseudoviruses relative to the Trimer, RBM hg , and Trivalent cohorts (Fig. 3A, S3A-E , 277 H). This is noteworthy for the Trimer hg cohort as it did not include any of these RBDs in the 278 immunization regimen. Similarly, the Cocktail hg cohort neutralized RaTG13 and SHC014, neither 279 of which were present in the immunogen. In contrast, the Trimer cohort was less potently 280 neutralizing against RaTG13, SARS-1, WIV1, and SHC014, and the RBM hg cohort trended 281 towards a loss in neutralization as well (Fig. S4A, B) . The Trivalent cohort also failed to neutralize 282 SARS-1 and trended towards a loss against RaTG13, WIV1, and SHC014. Immune imprinting by 283 priming with SARS-2 spike in the Trivalent cohort appears to have biased the subsequent serum 284 antibody response, which shows significantly greater neutralization of SARS-2 compared to both 285 SARS-1 and WIV1 despite the inclusion of all three components in the boosting immunizations. 

To further epitope map cross-reactive, RBM-focused serum responses, we performed ELISA-293 based antibody competition using cross-reactive antibodies CR3022, S309, ADI-55688, ADI-294 55689, and ADI-56046 with the WIV1 RBD ( Fig. 3B-D) . The latter three antibodies bind a 295 conserved sarbecovirus RBM epitope also targeted by the antibody ADG-2, which is currently in 296 clinical development and for which ADI-55688 is a precursor, as well as other antibodies with 297 broad sarbecovirus neutralization (Martinez et al., 2022; Rappazzo et al., 2021; Wec et al., 2020) . 298

Competition ELISAs, which we used to broadly bin serum antibody epitopes, suggest that the 299 cross-reactive WIV1-directed responses in the Trimer hg and Cocktail hg cohorts focus to the ADG-300 2-like epitope, as well as to the CR3022 and S309 epitopes in the Cocktail hg cohort (Fig. 3C-D) . 301 J o u r n a l P r e -p r o o f Thus, SARS-2 hg , rsSARS-1 hg , and rsWIV1 hg RBDs not only can induce potent SARS-2 302 neutralizing antibodies, but also cross-reactive antibodies that bind to a conserved RBM epitope. 303 304

Many SARS-2 variants of concern include mutations within the RBM including B.1.1.7 (Alpha), 306 B.1.351 (Beta), and P.1 (Gamma) first detected in the United Kingdom, South Africa, and Brazil, 307 respectively (Fig. S4C) . We evaluated how enhanced focusing to the RBM affected binding to 308 these variants. Serum from the Cocktail hg cohort showed no significant loss of binding to the 309 B.1.351 RBD compared to the wild-type SARS-2 RBD (Fig. S4D) Nanoparticles are commonly used to enhance immunogenicity by increasing overall avidity (Dai 334 et al., 2020); we therefore asked whether increasing copy number of our engineered immunogens 335 from 3 to 24 using ferritin-nanoparticles would improve overall immunogenicity and immune-336 focusing. We covalently attached SARS-2 hg RBD to ferritin nanoparticle using SpyTag-337

SpyCatcher; this engineered RBD is the same used in our Trimer hg cohort (Fig. 4A ) (Zakeri et al., 338 2012 ). Using the same immunization regimen as in the Trimer hg cohort allowed a direct 339 comparison to the antigenicity and immunogenicity due to valency. Importantly, the nanoparticle 340 immunogen did not elicit higher serum ELISA titers against the SARS-2 RBD (Fig. S5A, B) , 341 maintained RBM-focusing (Fig. 4B , C; S5C) and had comparable SARS-2 pseudovirus 342 neutralization titers (Fig. S5D) . However, the nanoparticle-boosted mice had markedly lower 343 neutralization titers against SARS-1 and WIV1 pseudoviruses (Fig. 4D ) and reduced neutralization 344 of SARS-2 variants (Fig. 4E, S5E) . These data suggest that at least for SARS-2 hg RBD, further 345 multimerization using a ferritin nanoparticle confers minimal, if any, functional advantage. 346 347

We next isolated a total of 85, 61, and 30 paired heavy and light chain sequences from SARS-2 350 RBD-specific IgG+ B cells from the Trimer, Trimer hg , and Cocktail hg cohorts, respectively (Fig.  351 S6A). Overall, there was a predominance of IGHV1-42 gene usage across all cohorts, but light 352 chain usage varied between the control Trimer cohort and the Trimer hg and Cocktail hg cohorts ( Fig.  353 S6B, C). CDRH3 length was significantly longer in the Trimer hg cohort, with a median of 12 amino 354 acids versus a median of 7 in both the Trimer and Cocktail hg cohorts (Fig. S6D) . Median somatic 355 hypermutation was relatively similar between the cohorts (Fig. S6E) . We chose 5 monoclonal 356 antibodies from 4 different clonally related populations isolated from the Trimer hg to express 357 recombinantly for further characterization (Fig. 5A , S6F-I; Table S1 ). The CDRH3s of these 358 clonally related populations were not shared with any antibodies isolated from the control Trimer 359 cohort. Ab19 and Ab20 were SARS-2 specific, did not bind the RBM hg construct, and did not 360 compete with CR3022, suggesting a largely RBM-directed epitope. Ab15 and the clonally related 361

Ab16 and Ab17 (Fig. S6H) were exceptionally broad in their reactivity, engaging all coronavirus 362 RBDs tested as well as the SARS-2 variant B.1.351 (Fig. 5A) . These antibodies still bound the 363 RBM hg construct and either completely (Ab15) or partially (Ab16, Ab17) competed with CR3022; 364 affinities to the B.1.351 and RBM hg construct were between ~2-20 fold lower than the affinity to 365 the SARS-2 RBD. These data suggest a conserved epitope that partially overlaps both the CR3022 366 epitope and the RBM, like that targeted by ADI-56046 (Wec et al., 2020) (Fig. S6J) . In addition 367 to their broad cross-reactivity, Abs 16 and 17 neutralized SARS-2, RaTG13, SARS-1, WIV1, and 368 SHC014 (Fig. 5B) . Furthermore, all antibodies neutralized P.1, and all except Ab19 neutralized 369 B.1.351. While Ab19 has no detectable affinity for RaTG13 as an Fab (Fig. 5A) , it still neutralizes 370 the pseudovirus as an IgG, suggesting that avidity is required. This indicates that RBM-focusing 371 can elicit antibodies capable of broadly neutralizing both related SARS-2 variants of concern and 372 diverse sarbecoviruses. 373

To define the epitope targeted by these Abs, we first obtained a low-resolution (~9.2 Å) cryo-EM 376 structure of Ab20 in complex with the SARS-2 spike (Fig. 6A ). Ab20 appears to target an epitope 377 on the upper loop of the SARS-2 RBM; its footprint likely will interfere with ACE2 binding and 378 is consistent with the observation that Ab20 does not bind the RBM hg with appreciable affinity. 379

Moreover, Ab20 has a significant reduction in affinity for B.1.351 RBD relative to the wild-type 380 SARS-2 RBD; mutation E484K within the RBM of B.1.351 appears to overlap with Ab20 381 footprint (Fig. S4C) . 382 383 We next obtained a low resolution (5.5 Å) cryoEM structure of Ab16 in complex with SARS-2 384 spike ( Fig. 6B-D) and determined a high-resolution crystal structure of the clonally related Ab17 385 in complex with the SARS-2 RBD (Fig. 6E-F) . In the cryoEM structure with Ab16, the SARS-2 386 spike is in the "three RBD up" conformation with density for each RBD to be occupied by a Fab. 387

Consistent with the reactivity from BLI, Ab16 appears to engage a conserved "class 4"-like epitope 388 (explaining observed competition with CR3022) that includes part of the RBM, and Ab16 likely 389 will sterically interfere with ACE2 binding (Barnes et al., 2020a) (Fig. 6C) . Furthermore, the 390 complex appears to show an outward rotation of the bound RBD relative to the previously 391 characterized "three RBD up" (PDB 7DX9) conformation (Fig. 6D) . Indeed, this was previously 392 hypothesized to contribute to SARS-1 neutralization by CR3022, and it may contribute to broad 393 neutralization by Ab16 and Ab17 as well (Yuan et al., 2020) . The higher-resolution co-crystal 394 structure of Ab17 in complex with the SARS-2 RBD provides a more complete view of the 395 antigen-combining site of these clonally related antibodies (Fig. 6E , Table S2 (Fig. 6F) . Importantly, the Ab16 and Ab17 epitope 402 is also left unmasked in the Trimer hg and Cocktail hg cohort boosting immunogens (Fig. 1A) , 403 allowing immune focusing to both conserved broadly neutralizing epitopes and the SARS-2 RBM. 404

Infection 407

Given that an RBM-focused immune response appears to be potently cross-neutralizing, we 408 evaluated whether refocusing the immune response towards the SARS-2 RBM following 409 imprinting with the SARS-2 spike was not inferior to maintaining an immune response directed 410 towards the full SARS-2 spike. We compared protection against infection in K18-hACE2 411 transgenic mice with a SARS-2 virus containing the D614G mutation following passive transfer 412 of sera collected at day 35 from the Trimer hg cohort (Fig. 7A ) (Winkler et al., 2020) . For 413 comparison, we used sera from mice that received SARS-2 spike protein ("Spike" cohort) three 414 times, as well as unimmunized control mice ("Unimmunized" cohort). In comparison to the 415 Unimmunized cohort, both the Trimer hg and Spike immunization regimens conferred significant 416 protection against weight loss (Fig. 7B) . We also compared viral burden by analyzing viral RNA 417 levels in the lung, heart, and nasal washes at 6 days post-infection. Within the lung and the heart, 418 both the Spike and Trimer hg sera conferred significant protection relative to the Unimmunized 419 cohort (Fig. 7C, D) . In nasal washes, there was a significant reduction in viral burden in the mice 420 that received the Spike sera relative to the Unimmunized cohort, but the difference among the mice 421 that received the Trimer hg sera only trended towards significance (Fig. 7E) . Across all metrics of 422 protection, there was not a significant difference between Spike sera and Trimer hg sera ( Fig. 7B -423 E). These data suggest that the Trimer hg sera is relatively equivalent to the Spike sera in terms of 424 protection conferred against severe SARS-2 infection and disease in mice and that refocusing the 425 serum immune response towards the RBM may confer potent cross-neutralization sarbecoviruses 426 without compromising protection against SARS-2. Currently approved vaccines, particularly mRNA-based vaccines, provide some protection against 441 SARS-2 variants of concern; however, it is unclear whether they will provide protection against 442 emerging sarbecoviruses, as some data show a substantial reduction in neutralization by vaccine- platforms can give rise to a scaffold-specific antibody response, which has the potential to alter 462 patterns of immune response. We saw no enhanced immunogenicity or immune focusing to the 463 SARS-2 RBM when boosting with SARS-2 hg -ferritin nanoparticles (Nanoparticle cohort) 464 compared to the trimerized SARS-2 hg construct (Trimer hg cohort). Rather, sera from the 465 Nanoparticle cohort demonstrated a reduced ability to neutralize related sarbecoviruses and SARS-466 2 variants of concern, suggesting that the ferritin nanoparticle-directed serum response may alter 467 the SARS-2-directed antibody response. Our engineered hyperglycosylated, cysteine-stabilized 468 GCN4 tag improves upon a previous hyperglycosylated version of the tag that already showed 469 markedly reduced immunogenicity (Sliepen et al., 2015) . In immunization regimens that aim to 470 immune focus, multimerizing immunogens with non-immunogenic scaffolds may confer the 471 benefits of increased avidity while contributing minimal additional epitopes that detrimentally alter 472 patterns of immunodominance. 473

Our study also shows how to use structure-guided hyperglycosylation and resurfacing to modulate 475 the immune response. We showed how the former strategy used in the Trimer hg and Cocktail hg 476 cohorts could direct responses to the SARS-2 RBM. However, our findings suggest that shielding 477 provided by engineered glycans may be imperfect. Comparing serum titers against RBM hg and 478 SARS-2 RBDs, the Cocktail hg appears to have increased RBM focusing relative to the Trimer hg 479 cohort. This possibly suggests that boosting with rsSARS-1 hg and rsWIV1 hg , rather than SARS-480 2 hg , results in increased focusing to the RBM. In other words, altering the epitopes presented in 481 the hyperglycosylated, non-RBM portion of the RBD likely contributes to this effect as 482 hyperglycosylation may not completely sterically occlude epitopes. Similarly, the RBM hg did not 483 fully abrogate binding to some RBM-directed antibodies, those that likely approach from angles 484 different from B38 or ACE2-both used to characterize our RBM hg RBD construct. The observed 485 differential binding to the RBM hg and SARS-2 RBD is only an approximation of the total RBM-486 directed antibody response. Nevertheless, our findings provide a framework upon which future 487 immunogen engineering efforts can build. These tools are broadly applicable to SARS-2 as well 488 as other viruses, including other coronaviruses. Our results also suggest that leveraging multiple 489 immunogen engineering approaches in combination can contribute to improved immune focusing. 490 491

Achieving pan-variant and pan-sarbecovirus immunity in the context of pre-existing immunity to 493 SARS-2 spike will be necessary; rationally designed immunogens that enable immune focusing to Collectively, our results demonstrate immunogen design approaches that can be leveraged to 507 refocus antibody responses following SARS-2 spike imprinting. Importantly, these design 508 strategies are not limited to coronaviruses and are adaptable to other viruses as a general approach 509 to elicit protective responses to conserved epitopes. Refocusing to the SARS-2 RBM maintains 510 protective SARS-2 neutralization while also eliciting antibody responses that recognize emerging 511 variants and potently neutralize coronaviruses with pandemic potential. Day 35 serum from all mice was assayed for neutralization against SARS-2, RaTG13, SARS-1, 579 WIV1, and SHC014 pseudoviruses (arranged in order of genetic similarity of the full-length spike 580 to SARS-2). Neutralization potency was computed using scaled endpoint serum ELISA titers. 581

Statistical significance was determined using the Kruskal-Wallis test with post-hoc analysis using 582

Dunn's test corrected for multiple comparisons (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** 583 = p < 0.0001, ns = not significant). Bars represent mean  SEM. Further information and requests for resources and reagents should be directed to and will be 654 fulfilled by the lead contact, Aaron G. Schmidt (aschmidt@crystal.harvard.edu). 655 656

All unique/stable reagents generated in this study will be made available on request, but we may 658 require a payment and/or a completed materials transfer agreement if there is potential for 659 commercial application. For non-commercial use, all unique/stable reagents generated in this 660 study are available from the lead contact with a completed materials transfer agreement. RBD. For samples with NT50 values below the limit of detection, the lowest limit of detection 807 across all neutralization assays was used as the NT50 value to calculate neutralization potency. 808

This prevents a higher limit of detection from skewing neutralization potency results. Endpoint 809 titers were normalized relative to a CR3022 IgG control, which was run in every serum ELISA. 810 ELISA titers that were too low to calculate an endpoint titer were set to 40, which was the starting 811 point for the serum dilutions. 812

In comparing NT50 values for the various cohorts across the wild-type and variant pseudoviruses, 814 the lowest limit of detection across all neutralization assays performed for a given cohort was used 815 for any NT50 values that fell below the limit of detection. This prevents a higher limit of detection 816 in some assays from skewing the comparison results. were extracted from motion-corrected micrographs and subjected to 2D classification, initial 3D 869 model generation, 3D classification, and 3D refinement. Ab16 was C3 symmetric. CTF refinement 870 was performed to correct beam tilt, trefoil, anisotropic magnification, and per particle defocus in 871 RELION (Scheres, 2012) . Bayesian polishing was also performed in RELION leading to a 6.6 Å 872 reconstruction following 3D refinement. The final 3D refined map was sharpened with a B-factor 873 of −297.5 Å 2 resulting in a 5.5 Å resolution map as determined by the Fourier shell correlation 874 (0.143 cutoff) (Fig. S7A) . Heavy and light chains of PDB entries 6LHQ and 4HC1 were aligned 875 and extracted to make an initial model for the Fab. Spike with 3 RBD in the "up" conformation 876 (PDB 7DX9) and model of Ab16 Fab were docked into the cryoEM map using Chimera (Fig. 6B-877   D) . 878 879 Micrographs from Ab20 in complex with spike were processed as above for Ab16. Most particles 880 exhibited C1 symmetry due to conformational heterotgeneity of the RBD relative to the S2 core 881 of spike. Accordingly, particles with C3 symmetry were isolated by 3D classification for further 882 refinement. CTF refinement was performed to correct beam tilt, trefoil, anisotropic magnification, 883 and per particle defocus in RELION (Scheres, 2012) . Bayesian polishing was also performed in 884 RELION leading to a 10 Å reconstruction following 3D refinement. The final 3D refined map was 885 sharpened with a B-factor of -768 Å 2 resulting in a 9.2 Å resolution map as determined by the 886 Fourier shell correlation (0.143 cutoff) (Fig. S7B) . Heavy and light chains of PDB entries 4L5F 887 and 4HC1 were aligned and extracted to make an initial model for the Fab. Spike with 3 RBD in 888 the "down" conformation (PDB 6VXX) and model of Ab20 Fab were docked into the cryoEM 889 map using Chimera (Pettersen et al., 2004) (Fig. 6A) . 

• Rationally designed immunogens using glycan engineering and epitope scaffolding.

• Immunogens focus murine antibody responses following SARS-2 spike imprinting.

• Focusing to the SARS-2 receptor binding motif yields broad, potent neutralization.

• Structural characterization of immunogen-elicited mAbs defines conserved epitopes.

Hauser et al. use structure-guided design to engineer SARS-2 immunogens that direct immune responses to conserved viral sites in context of preexisting immunity. In mice, these immunogens elicit antibodies that potently neutralize related coronaviruses, including those of potential pandemic concern. Structural characterization of selected antibodies explains this observation. Figure S1 (related to Fig. 1) . Biochemical validation of resurfaced and hyperglycosylated immunogens. (A) SDS-Page gel analysis of the SARS-2 receptor binding motif (RBM) construct with HRV 3C-cleavable 8xHis and streptavidin binding peptide (SBP) tags. Gel lanes containing unrelated samples have been removed. (B) ACE2 cell binding assay results for the SARS-2 RBM construct at 1 µM. (C) After grafting the SARS-2 RBM onto the SARS-1 and WIV1 RBDs, conformationally specific Fabs B38 and CR3022 were used to confirm that these epitopes remained intact with comparable affinity to wild-type (9.7*10 -7 M for B38 Fab and SARS-2 RBD; 2.7*10 -8 M for CR3022 Fab and SARS-1 RBD; 3.7*10 -8 M for CR3022 Fab and WIV1 RBD). FAB2G sensors were used with immobilized fabs. rsSARS-1 and rsWIV1 were the analytes. Titrations with B38 Fab were performed at 10 µM, 5 µM, 1 µM, and 0.5 µM. Titrations with CR3022 Fab were performed at 10 µM and 5 µM. Vendor-supplied software was used to generate an apparent KD, or an approximate KD in the case of titrations with two runs. (D) Candidate glycans were tested individually in the context of the SARS-CoV-2 RBD. All glycans were designed to mask epitopes outside the RBM. Therefore, biochemical validation was performed by assessing binding to the RBM-directed conformationally specific antibody B38 via single-hit BLI using FAB2G sensors with the RBD of interest as the analyte at 10 µM. Binding to ACE2 was also assessed via an ACE2 cell binding assay with antigen concentrations at 1 µM. Binding was binned subjectively into three categories: minimal (red), substantially reduced (yellow), and roughly intact (green). (E) Conformationally specific Fab B38 was used to assess continued accessibility of the SARS-2 RBM in both monomeric and trimeric hyperglycosylated constructs. FAB2G sensors were used with immobilized fabs; hyperglycosylated coronavirus proteins were the analytes. Titrations with B38 Fab were performed at 7.5 µM, 5 µM, 2.5 µM, and 1 µM (rsSARS-1 hg trimer, rsWIV1 hg trimer); 5 µM, 2.5 µM, 1 µM, and 0.5 µM (SARS-2 hg trimer, SARS-2 hg monomer); 10 µM, 7.5 µM, 5 µM, 3.75 µM, and 2.5 µM (rsWIV1 hg monomer); 10 µM, 7.5 µM, 5 µM, and 2.5 µM (rsSARS-1 hg monomer). Vendor-supplied software was used to generate an apparent KD. (F) BLI with conformationally specific Fabs CR3022 and S309 at 10 µM was compared to loading controls for each of the hyperglycosylated monomers. The similarity in these traces to the noantibody loading control confirms a lack of binding. (G) ACE2 cell binding assay results for resurfaced and hyperglycosylated constructs at 1 µM. Figure S2 (related to Fig. 1). Immunogen production and biochemical validation. (A, B) Design and expression of two different versions of the SARS-2 RBD with additional putative Nlinked glycosylation sites (PNGs) engineered onto the RBM. One construct has glycosylation sites at positions 475 and 501, while the other construct has glycosylation sites at positions 475, 501, 448, and 496. The latter is the RBM hg construct. ACE2 is shown in cyan, the RBM is shown in red, and the non-RBM portion of the SARS-2 RBD is shown in purple. (PDB: 6M0J) (C) The presence of glycans at positions 475 and 501 alone is sufficient to abrogate ACE2 binding to the RBM. (D) Representative size exclusion trace with (*) marking the trimeric constructs. Fractions in this peak were pooled and used for immunizations. Quantity of Expi293 transfection is in parentheses next to each label. (E) SDS-PAGE analysis of purified trimers following removal of the affinity purification tags under non-reducing (NR) and reducing (R) conditions. The engineered disulfide bond at the C-terminus of the hyperglycosylated GCN4 tag separated under reducing Figure S3 (related to Fig. 2) . Serum antigenicity assessed via ELISA. Serum following immunizations from the Trimer (A), Trimer hg (B), Cocktail hg (C), RBM hg (D), and Trivalent (E) cohorts was assayed in ELISA at day 35 with different coronavirus antigens. Bars represent mean ± SEM. The SARS-2 spike refers to the double-proline stabilized spike used in the prime immunization, while all of the other coating antigens are RBDs. Statistical significance was determined using Kruskal-Wallis test with post-hoc analysis using Dunn's test corrected for multiple comparisons, and pairwise comparisons without pictured bars were not significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001). Selected titers from Fig. S3A -E are shown in Fig. 2A ; differences in levels of statistical significance are due to the fact that multiple comparisons were performed in Fig. S3A-E. (F) A serum ELISA was performed for Trivalent cohort with an irrelevant protein (influenza hemagglutinin head) tagged with the hyperglycosylated GCN4 tag (HA-GCN4) to measure tag-directed antibody responses. The Trivalent cohort was selected because it had the highest serum ELISA titers. For the coating HA-GCN4 protein, a purification size exclusion trace (fractions in the peak marked with "*" were pooled) and an SDS-PAGE gel run under non-reducing (NR) and reducing (R) conditions are shown. Gel lanes containing unrelated samples have been removed. (G) Serum ELISAs were performed against the relevant hyperglycosylated immunogens for the Trimer hg and Cocktail hg cohorts. There was no statistically significant difference in endpoint titers within the Trimer hg or Cocktail hg cohorts across these coating antigens, as determined by the Mann-Whitney U test and the Kruskal-Wallis test, respectively. Bars represent mean ± SEM. (H) For all cohorts, day 35 serum samples were used in ELISAs to assess binding to RaTG13 and SHC014 RBDs. Bars represent mean ± SEM. No statistical comparisons were performed.

J o u r n a l P r e -p r o o f Figure S4 (related to Fig. 3) . Neutralization against related sarbecoviruses and SARS-2 variants of concern. (A) Day 35 serum from all mice was assayed for neutralization against SARS-2, RaTG13, SARS-1, WIV1, and SHC014 pseudoviruses. Statistical significance was determined using the Kruskal-Wallis test with post-hoc analysis using Dunn's test corrected for multiple comparisons, and pairwise comparisons without pictured bars were not significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001). Bars represent mean ± SEM. (B) Pseudovirus neutralization assays were used to calculate NT50 values for SARS-2, SARS-1, WIV1, RaTG13, and SHC014 from all cohorts. All NT50s are from day 35 sera. Statistical significance was determined using the Kruskal-Wallis test with post-hoc analysis using Dunn's test corrected for multiple comparisons in the case of a significant Kruskal-Wallis test, and pairwise comparisons without pictured bars were not significant (* = p < 0.05). Bars represent mean ± SEM. (C) Structural depiction of SARS-2 variant RBD mutations for B.1.351 (red), as well as ACE2 contact residues (cyan). (PDB: 6M0J) Sequences depict all spike mutations across select variants. (D) Day 35 serum was assayed in ELISA against SARS-2 RBD (WT) and SARS-2 RBD with K417N, E484K, and N501Y mutations (B.1.351). Statistical significance was determined using the Wilcoxon sign rank test (* = p < 0.05, ** = p < 0.01; ns = not significant). (E) Pseudovirus neutralization assays were used to calculate NT50 values for P.1, B.1.1.7, and B.1.351 from all cohorts. All NT50s are from day 35 sera. Statistical significance was determined using the Kruskal-Wallis test; no pairwise differences are statistically significant. Bars represent mean ± SEM. Figure S5 (related to Fig. 4) . Serum antigenicity for the Nanoparticle cohort. (A) Serum following immunization was assayed in ELISA at day 35 with different coronavirus antigens. Statistical significance was determined using the Kruskal-Wallis test with post-hoc analysis using Dunn's test corrected for multiple comparisons, and pairwise comparisons without pictured bars were not significant (* = p < 0.05, ** = p < 0.01, *** = p < 0.001). Bars represent mean ± SEM. (B) Comparison of day 35 SARS-2 RBD ELISA endpoint titers in the Nanoparticle and Trimer hg cohorts. Statistical significance was determined using the Mann-Whitney U test (ns = not significant). Bars represent mean ± SEM. (C) Day 35 serum samples assayed against rsSARS-1 and rsWIV1 RBDs no longer show statistically significant differences in binding compared to SARS-2 RBD as determined using the Kruskal-Wallis test with post-hoc analysis using Dunn's test corrected for multiple comparisons. Bars represent mean ± SEM. (D) Comparison of day 35 SARS-2 pseudovirus neutralization in the Nanoparticle and Trimer hg cohorts. Statistical significance was determined using the Mann-Whitney U test (ns = not significant). Bars represent Spleens were harvested at day 42 and SARS-2 RBD-directed IgG+ B cells were isolated via flow cytometry and sequenced. B cell receptor sequencing was used to characterize (B) heavy and (C) light chain V-gene usage. All gene families listed are *01 except VH1-84*02. Complementarity determining region 3 (CDR3) length (D) and percent somatic hypermutation (SHM) (E) were also analyzed for each sequence. SHM was not analyzed for cohorts with uncertain IMGT V-gene assignments. Statistical significance was determined using the Kruskal-Wallis test with post-hoc analysis using Dunn's test corrected for multiple comparisons, and pairwise comparisons without pictured bars were not significant (* = p < 0.05, ** = p < 0.01). Bars represent mean ± SEM. Within each mouse, clonal lineages were analyzed on the basis of CDRH3 similarity. CDRH3 groupings are represented by count (F) and proportion (G) within each mouse. Not all sequences were successfully grouped into lineages. (H) Phylogenetic tree of a large clonal lineage containing Ab16 and Ab17 generated using Cloanalyst to infer common ancestors. (I) BLI was performed using Fabs representative of lineages expanded in RBM-focusing cohorts. Ni-NTA biosensors were used with Fabs bound to the sensor using the 8xHis tag and RBDs in solution as the analyte. Titrations were performed at 10 µM, 5 µM, 2.5 µM, and 1 µM. Vendor-supplied software was used to generate an apparent KD. (J) Conformationally specific Fabs ADI-55688, ADI-55689, and ADI-56046, which target a conserved RBM epitope, were used to assess binding to the RBM hg , SARS-2 hg , rsSARS-1 hg , and rsWIV1 hg monomers via BLI. FAB2G sensors were used with immobilized fabs; coronavirus proteins were the analytes. Titrations were performed at 10 µM, 5 µM, 2.5 µM, and 1.25 µM (SARS-2 RBD and SARS-2 hg with ADI-55689, SARS-2 RBD and SARS-2 hg with ADI-56046, all titrations with RBM hg ); 3 µM, 1.5 µM, 0.75 µM, and 0.375 µM (rsSARS-1 hg and rsWIV1 hg with ADI-56046); 10 µM, 5 µM, 2.5 µM, and 1 µM (all titrations with ADI-55688 except RBM hg ). Minimal binding was detected to ADI-55689 Fab with rsSARS-1 hg and rsWIV1 hg . Vendor-supplied software was used to generate an apparent KD. . 6) . Crystallographic data and refinement statistics. Statistics for the highest-resolution shell are shown in parentheses. 

Proof of principle for epitope-focused 999 vaccine design

Protocol and Reagents for Pseudotyping 1002

Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Structure and Immune Recognition of the HIV 1004 Glycan Shield

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

Disquisitions of Original Antigenic Sin. I. Evidence 1009 in man

Transmission of MERS-coronavirus in 1012 household contacts

Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

Coot: model-building tools for molecular graphics

Scaling and assessment of data quality

An introduction to data reduction: space-group determination, scaling and 1022 intensity statistics

How good are my data and what is the resolution? 1024

COVID-19-neutralizing 1027 antibodies predict disease severity and survival

CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Antibodies elicited by mRNA-1273 vaccination bind more 1033 broadly to the receptor binding domain than do those from SARS-CoV-2 infection

Studies in humanized mice and convalescent humans yield a 1037 SARS-CoV-2 antibody cocktail

A SARS-CoV-2 Infection Model in 1040 Mice Demonstrates Protection by Neutralizing Antibodies

Safety Monitoring of an Additional Dose of COVID-19 Vaccine -United States

Broadly neutralizing antibodies to SARS-related 1046 viruses can be readily induced in rhesus macaques

Coronavirus infections in 1048 working adults. Eight-year study with 229 E and OC 43

Structure-based design of prefusion-stabilized 1051 SARS-CoV-2 spikes

SARS-CoV-2 RBD Neutralizing Antibody Induction is 1054 Enhanced by Particulate Vaccination

Characterization of 1056 influenza antibodies by serum absorption

The neutralizing 1059 antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Integration, scaling, space-group assignment and post-refinement

Xds

Loss of Bcl-6-Expressing T 1068 Follicular Helper Cells and Germinal Centers in COVID-19

Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding 1071 Domain Self-Assembled Nanoparticle Vaccine Candidates

Reconstructing a B-Cell Clonal 1074

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 1077 receptor

Functional assessment of cell entry and receptor 1079 usage for SARS-CoV-2 and other lineage B betacoronaviruses

Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of 1082 SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys

Cross-Neutralization of a SARS-CoV-2 Antibody to a 1086 Functionally Conserved Site Is Mediated by Avidity

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 1089 neutralizing antibody response

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad 1092 Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses

Chimeric spike mRNA vaccines 1096 protect against sarbecovirus challenge in mice

A broadly cross-reactive antibody neutralizes and protects 1099 against sarbecovirus challenge in mice

Automated electron microscope tomography using robust prediction 1101 of specimen movements

Phaser crystallographic software

A SARS-like cluster of 1106 circulating bat coronaviruses shows potential for human emergence

SARS-like WIV1-CoV poised 1109 for human emergence

The Tecumseh study of respiratory illness. VI. Frequency of 1111 and relationship between outbreaks of coronavirus infection

Retroviruses pseudotyped with the severe acute 1114 respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-1115 converting enzyme 2

Effectiveness of Pfizer-BioNTech and Moderna 1118 Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and 1119

During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant -National 1120

Elicitation of structure-specific antibodies by epitope scaffolds

UCSF Chimera--a visualization system for exploratory research and 1127 analysis

Mapping Neutralizing and 1130 Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-1131 Guided High-Resolution Serology

Cross-neutralization of SARS-CoV-2 by a 1134 human monoclonal SARS-CoV antibody

Sensitivity of infectious SARS-CoV

1.1.7 and B.1.351 variants to neutralizing antibodies

Impact of Delta on viral burden and vaccine 1140 effectiveness against new SARS-CoV-2 infections in the UK. medRxiv

Dipeptidyl peptidase 4 is a functional receptor for 1143 the emerging human coronavirus-EMC

Broad and potent activity against 1146 SARS-like viruses by an engineered human monoclonal antibody

Systematic design and testing of nested (RT-)PCR 1148 primers for specific amplification of mouse rearranged/expressed immunoglobulin variable 1149 region genes from small number of B cells

Hospitalizations Among Adults, by Vaccination Status

Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing 1157 Response against Influenza Virus

Lessons for COVID-19 Immunity from Other Coronavirus 1159 Infections

Neutralizing antibody vaccine for pandemic and pre-1162 emergent coronaviruses

RELION: implementation of a Bayesian approach to cryo-EM structure 1164 determination

Immunogenic Stimulus for Germline Precursors of Antibodies 1167 that Engage the Influenza Hemagglutinin Receptor-Binding Site

Viral receptor-binding site antibodies with diverse germline 1170 origins

Rises in titers of 1172 antibody to human coronaviruses OC43 and 229E in Seattle families during 1975-1979

Structural basis of receptor recognition by SARS-CoV-2

Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and 1178 Reports. medRxiv

Glycan engineering of the SARS-CoV-2 1181 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses

Affordable luciferase reporter assay for cell-based high-throughput 1185 screening

Immunosilencing a highly immunogenic protein trimerization domain

Reduced neutralization of 1191 SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Neutralizing and protective human 1194 monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Iterative model building, structure refinement and 1198 density modification with the PHENIX AutoBuild wizard

Six Month Safety and Efficacy of the 1202 BNT162b2 mRNA COVID-19 Vaccine

Cloning and expression of murine Ig genes 1204 from single B cells

Memory B cell repertoire for recognition 1207 of evolving SARS-CoV-2 spike

Elicitation of Potent Neutralizing Antibody Responses 1210 by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Elicitation of broadly protective 1213 sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

Ferritin nanoparticle-based 1216 SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in 1217 mice

mRNA vaccine-elicited 1220 antibodies to SARS-CoV-2 and circulating variants

In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine 1223 candidates

Original antigenic sin in ferrets: the response to sequential infections with 1225 influenza viruses

Broad neutralization of SARS-related viruses 1228 by human monoclonal antibodies

SARS-CoV-2 1231 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

SARS-CoV-2 infection of human ACE2-transgenic mice 1234 causes severe lung inflammation and impaired function

Cryo-EM structure of the 2019-nCoV spike in the prefusion 1237 conformation

Serum Neutralizing Activity Elicited by 1240 mRNA-1273 Vaccine

Duration of antibody responses after severe acute 1243 respiratory syndrome

A natural mutation between SARS-CoV-2 and SARS-CoV 1246 determines neutralization by a cross-reactive antibody

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding 1249 to its receptor ACE2

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective 1252 immunity

Structural and functional ramifications of antigenic drift in 1255 recent SARS-CoV-2 variants

1257 (2020). A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and 1258 SARS-CoV

Peptide tag forming a rapid covalent bond to a protein, through engineering a 1261 bacterial adhesin

Evidence of escape of SARS-1264

CoV-2 variant B.1.351 from natural and vaccine-induced sera

Evidence of escape of SARS-1267

Monomeric SARS-2 RBD was titrated at 10 µM, 1 µM, 500 nM, and 100 nM with B38 Fab and at 10 µM, 5 µM, 750 nM, and 250 nM with CR3022 Fab. Apparent KD was obtained by vendor-supplied software. (H) SDS-Page gel analysis of purified and cleaved trimeric constructs under non-reducing (NR) and reducing (R) conditions, showing the dissociation of the disulfide bond in the hyperglycosylated GCN4 tag (hgGCN4 cys ) under reducing conditions. Gel lanes containing unrelated samples have been removed. (I) Representative size exclusion chromatography traces for trimeric constructs. The trimer peak is marked with "*", and fractions from this peak were pooled for HRV 3C cleavage and use as immunogens. Quantity of Expi293 transfection is in parentheses next to each label. (J) Protein yields for purified trimeric hyperglycosylated constructs in Expi293 cells

We thank members of the Schmidt Laboratory for helpful discussions. We

J o u r n a l P r e -p r o o f The table highlights the reagents, genetically modified organisms and strains, cell lines, software, instrumentation, and source data essential to reproduce results presented in the manuscript. Depending on the nature of the study, this may include standard laboratory materials (i.e., food chow for metabolism studies, support material for catalysis studies), but the table is not meant to be a comprehensive list of all materials and resources used (e.g., essential chemicals such as standard solvents, SDS, sucrose, or standard culture media do not need to be listed in the table). Items in the table must also be reported in the method details section within the context of their use. To maximize readability, the number of oligonucleotides and RNA sequences that may be listed in the table is restricted to no more than 10 each. If there are more than 10 oligonucleotides or RNA sequences to report, please provide this information as a supplementary document and reference the file (e.g., See Table S1 for XX) in the key resources table.

Please note that ALL references cited in the key resources table must be included in the references list. Please report the information as follows:• REAGENT or RESOURCE: Provide full descriptive name of the item so that it can be identified and linked with its description in the manuscript (e.g., provide version number for software, host source for antibody, strain name • SOURCE: Report the company, manufacturer, or individual that provided the item or where the item can be obtained (e.g., stock center or repository). For materials distributed by Addgene, please cite the article describing the plasmid and include "Addgene" as part of the identifier. If an item is from another lab, please include the name of the principal investigator and a citation if it has been previously published. If the material is being reported for the first time in the current paper, please indicate as "this paper." For software, please provide the company name if it is commercially available or cite the paper in which it has been initially described.• IDENTIFIER: Include catalog numbers (entered in the column as "Cat#" followed by the number, e.g., Cat#3879S). Where available, please include unique entities such as RRIDs, Model Organism Database numbers, accession numbers, and PDB, CAS, or CCDC IDs. For antibodies, if applicable and available, please also include the lot number or clone identity. For software or data resources, please include the URL where the resource can be downloaded. Please ensure accuracy of the identifiers, as they are essential for generation of hyperlinks to external sources when available. Please see the Elsevier list of data repositories with automated bidirectional linking for details. When listing more than one identifier for the same item, use semicolons to separate them (e.g., Cat#3879S; RRID: AB_2255011). If an identifier is not available, please enter "N/A" in the column. o A NOTE ABOUT RRIDs: We highly recommend using RRIDs as the identifier (in particular for antibodies and organisms but also for software tools and databases). For more details on how to obtain or generate an RRID for existing or newly generated resources, please visit the RII or search for RRIDs.Please use the empty table that follows to organize the information in the sections defined by the subheading, skipping sections not relevant to your study. Please do not add subheadings. To add a row, place the cursor at the end of the row above where you would like to add the row, just outside the right border of the